Results 191 to 200 of about 65,592 (243)

Revisiting the Immune Frontier in Soft Tissue Sarcomas. [PDF]

Curr Oncol Rep
Bilani N, Al Akoum N, Al-Marayaty R, Orlando S, Alexiev B, de Viveiros PH, Pollack SM.   +6 more
europepmc   +1 more source

Comparison of real-world efficacy and safety of nivolumab plus ipilimumab or pembrolizumab combined with platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer in a German population. [PDF]

Cancer Immunol Immunother
Weber M, Freiherr von Hammerstein-Equord A, Weinreich M, Andreas S, Rittmeyer A.   +4 more
europepmc   +1 more source

First-line ipilimumab plus nivolumab in advanced merkel cell carcinoma: a meta-analysis of prospective trials and real-world validation cohort. [PDF]

Cancer Immunol Immunother
Ramadoss T, Palacios C, Nichols M, Eroglu Z, Markowitz J, Karapetyan L, Tarhini AA, Wuthrick EJ, Sondak VK, Tsai KY, Khushalani NI, Brohl AS.   +11 more
europepmc   +1 more source

Immune Checkpoint Inhibitor-Related Hypophysitis and Pituitary Dysfunction: A Systematic Review of Diagnosis and Management. [PDF]

Cureus
SirDeshpande P, Hegde SBS, Akhtar H.
europepmc   +1 more source

Clinical and translational results from a phase 1 trial of gemcitabine/nab-paclitaxel with nivolumab/ipilimumab or hydroxychloroquine/ipilimumab in untreated metastatic pancreatic adenocarcinoma. [PDF]

J Immunother Cancer
O'Reilly EM, Cabanski CR, Lyman JP, Wainberg ZA, Fisher GA, Wolff RA, Ko AH, O'Hara MH, Spencer CN, Yu JX, Da Silva DM, Padrón LJ, Arnott J, Fairchild J, Moore JS, Peng B, Hoos WA, O'Donnell-Tormey J, Boffo S, Dugan U, Kimmelman AC, Amaravadi RK, Vonderheide RH.   +22 more
europepmc   +1 more source

Hematological toxicities and thrombosis risk associated with immune checkpoint inhibitors: a pharmacovigilance study from 2014 to 2024. [PDF]

Cancer Immunol Immunother
Hou J, Mu G, Zhang Z, Xiang Q, Cui Y.
europepmc   +1 more source

A combination of low TMB and PD-L1 expression predict poor progression-free survival of metastatic melanoma patients treated with first-line ipilimumab plus nivolumab. [PDF]

Front Immunol
Akhavan B, Samlowski W.
europepmc   +1 more source

A Minimum 3-Year Follow-Up of Nivolumab-Plus-Ipilimumab in Japanese Patients With Advanced or Metastatic Renal Cell Carcinoma: A Final Analysis of the J-ENCORE Study. [PDF]

Int J Urol
Hamamoto S, Nozawa M, Shirotake S, Sazuka T, Numakura K, Mizokami A, Kondo T, Naito S, Abe T, Ohba K, Kimura G, Nagata M, Onodera S, Yamaguchi K, Uemura H.   +14 more
europepmc   +1 more source

Associations of Tumor Somatic Mutations and Genetic Alterations with Survival Outcomes in Melanoma Patients Treated with Ipilimumab. [PDF]

J Clin Med
Khaksar MA, Eljilany I, Yassine I, Yu X, Teer JK, Conejo-Garcia JR, Lyons M, LaFramboise W, Tarhini AA.   +8 more
europepmc   +1 more source